Variation in Recombinant Zoster Vaccine Uptake and Completion by Utilization of Office-Based Vaccination
Author(s)
Nikita Stempniewicz, MSc1, Catherine B. McGuiness, MA, MS2, Chi-Chang Chen, PhD, MsPharm2, Marie Yasuda, PharmD, MS2, Dajun Tian, PhD2, Daniel Verdi, MD1, Justin Gatwood, PhD, MPH1;
1GSK, Philadelphia, PA, USA, 2IQVIA, Wayne, PA, USA
1GSK, Philadelphia, PA, USA, 2IQVIA, Wayne, PA, USA
Presentation Documents
OBJECTIVES: To compare recombinant zoster vaccine (RZV) administration location across US health care organizations (HCOs) and primary care providers (PCPs).
METHODS: This retrospective study utilized 5 years (2018-2022) of IQVIA open-source US claims and included a sample of HCOs across geographic regions and organization sizes. Included patients were aged ≥50 years as of 01/01/2022 and had ≥2 preventative or evaluation and management visits with the same PCP (≥1 visit in 2022 and ≥1 visit in 2018-2021), to which they were attributed based on their most recent visit (PCPs with <30 attributed patients were excluded). Receipt of RZV was measured using medical and pharmacy claims from any setting. Office-based vaccination was defined as the proportion of patients receiving their first RZV dose in a physician’s office and was described overall and by PCP and HCO. PCPs were grouped into high and low office-based vaccination groups using the median proportion of office-based vaccination across all PCPs. RZV uptake (≥1 dose) and series completion (within 12 months) proportions were described among their attributed patients.
RESULTS: Overall, 51 HCOs, 4,113 PCPs, and 1,459,230 patients were included. Mean (standard deviation) patient age was 67 (10) years; 56% were female. Overall, 24% of patients received their first RZV dose in a physician’s office, ranging from 0-46% across HCOs, and 0-100% across PCPs. The median proportion of office-based vaccination among PCPs was 8%. Patients seen by PCPs with high proportions of office-based vaccination had numerically higher overall uptake (42%) compared to those seen by PCPs with low proportions of office-based vaccination (28%); however, their series completion was numerically lower (80% versus 84%).
CONCLUSIONS: Office-based vaccination was highly variable across the HCOs and PCPs examined and may impact RZV uptake and completion. Additional efforts and research may be warranted to support series completion when initiated in a physician’s office. Funding: GSK (VEO-000676).
METHODS: This retrospective study utilized 5 years (2018-2022) of IQVIA open-source US claims and included a sample of HCOs across geographic regions and organization sizes. Included patients were aged ≥50 years as of 01/01/2022 and had ≥2 preventative or evaluation and management visits with the same PCP (≥1 visit in 2022 and ≥1 visit in 2018-2021), to which they were attributed based on their most recent visit (PCPs with <30 attributed patients were excluded). Receipt of RZV was measured using medical and pharmacy claims from any setting. Office-based vaccination was defined as the proportion of patients receiving their first RZV dose in a physician’s office and was described overall and by PCP and HCO. PCPs were grouped into high and low office-based vaccination groups using the median proportion of office-based vaccination across all PCPs. RZV uptake (≥1 dose) and series completion (within 12 months) proportions were described among their attributed patients.
RESULTS: Overall, 51 HCOs, 4,113 PCPs, and 1,459,230 patients were included. Mean (standard deviation) patient age was 67 (10) years; 56% were female. Overall, 24% of patients received their first RZV dose in a physician’s office, ranging from 0-46% across HCOs, and 0-100% across PCPs. The median proportion of office-based vaccination among PCPs was 8%. Patients seen by PCPs with high proportions of office-based vaccination had numerically higher overall uptake (42%) compared to those seen by PCPs with low proportions of office-based vaccination (28%); however, their series completion was numerically lower (80% versus 84%).
CONCLUSIONS: Office-based vaccination was highly variable across the HCOs and PCPs examined and may impact RZV uptake and completion. Additional efforts and research may be warranted to support series completion when initiated in a physician’s office. Funding: GSK (VEO-000676).
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HSD18
Topic
Health Service Delivery & Process of Care
Disease
STA: Vaccines